Page 83 - Human Use News Today

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates...

WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic

Financial Results & Corporate Update 4th Quarter and Full Year 2022 27.03.2023 This Slide Presentation Includes... | March 27, 2023

Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer... | March 27, 2023

The MHRA announced on Tuesday the biggest overhaul of clinical trial regulation in the UK in 20 years. The details of the amendments to clinical trial regulation are set out in the...

First of a series on cybernetics, Mark Pesce explains how we learned to use and control the information generated by all the processes of civilisation

In 2022, FDA had a very productive year with the approval of hundreds of generic drugs.

We have quality systems in place across GSK to ensure we meet the high standards we set ourselves as a company

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Addition of ravulizumab to BSC did not improve survival or other secondary outcomes. Safety findings were consistent with the known safety profile of ravulizumab in its approved indications. Despite the lack of efficacy, the study adds value for future research into complement therapeutics in critical illnesses by showing that C5 inhibition can be accomplished in severely ill patients.